PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Heart, Lung and Circulation10.1016/j.hlc.2018.04.175201827S563Trend Analysis for the Choice and Cost of Lung Cancer Treatment in South Korea, 2003–13Dohun Kim, So Young Kim, Beomseok Suh, Jong Hyock Parkhttps://api.elsevier.com/content/article/PII:S1443950618303469?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1443950618303469?httpAccept=text/plain
Cancer Research and Treatment10.4143/crt.2017.0502018503757-767Trend Analysis for the Choice and Cost of Lung Cancer Treatment in South Korea, 2003-2013Dohun Kim, So Young Kim, Beomseok Suh, Jong Hyock Parkhttp://e-crt.org/upload/pdf/crt-2017-050.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2017.050, http://www.e-crt.org/upload/pdf/crt-2017-050.pdf
Lung Cancer10.1016/j.lungcan.2013.08.0212013823461-468A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysisRichard E. Nelson, David Stenehjem, Wallace Akerleyhttps://api.elsevier.com/content/article/PII:S0169500213003863?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500213003863?httpAccept=text/plain
Lung Cancer10.1016/s0169-5002(03)92035-6200341S107P-66 Trend of lung cancer in recent 5 years; Analysis as viewed from age, gender, pathological types, stage of disease, therapeutic modality, and prognosisMitsuhiro Matsumotohttps://api.elsevier.com/content/article/PII:S0169500203920356?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500203920356?httpAccept=text/plain
Lung Cancer10.1016/s0169-5002(13)70190-9201379S66190 Tolvaptan – cost effective treatment of SIADH in malignanciesJ. Shakher, J. Thompsonhttps://api.elsevier.com/content/article/PII:S0169500213701909?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500213701909?httpAccept=text/plain
Lung Cancer10.1016/s0169-5002(03)91670-9200341S7-S8O-12 The cost effectiveness (CE) and cost to medicare of gefitinib (Iressa; ZD1839) for the third-line treatment of non-small cell lung cancer (NSCLC): Can medicare afford the bill?Thomas Gerald Roberts, Thomas James Lynchhttps://api.elsevier.com/content/article/PII:S0169500203916709?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500203916709?httpAccept=text/plain
Journal of Medical Imaging and Radiation Oncology10.1111/j.1754-9485.2012.02354.x2012562235-241Cost analysis of lung cancer management in South Western SydneySharlyn Kang, Eng-Siew Koh, Shalini K. Vinod, Bin Jalaludinhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1754-9485.2012.02354.x, http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1754-9485.2012.02354.x/fullpdf
Lung Cancer10.1016/s0169-5002(03)91939-8200341S82O-281 Cost analysis of video-assisted thoracic surgery (VATS) versus thoracotomy: Critical reviewPaul E. Van Schilhttps://api.elsevier.com/content/article/PII:S0169500203919398?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500203919398?httpAccept=text/plain
Lung Cancer10.1016/s0169-5002(13)70268-x201380S20-S2147P TREATMENT OPTIONS FOR SMALL CELL LUNG CANCER: DOES LANREOTIDE REPRESENT A NEW CHOICE?T. Franchina, C. Proto, A. Russo, G. Chiofalo, A. Scimone, V. Adamohttps://api.elsevier.com/content/article/PII:S016950021370268X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S016950021370268X?httpAccept=text/plain
Cancer Research and Treatment10.4143/crt.2022.8822023552570-579Quality Assessment and Trend for Breast Cancer Treatment Practice across South Korea Based on Nationwide Analysis of Korean Health Insurance Data during 2013-2017Kyu Hye Choi, Soo-Yoon Sung, Sea-Won Lee, Ye Won Jeon, Sung Hwan Kim, Jong Hoon Leehttp://e-crt.org/upload/pdf/crt-2022-882.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2022.882, http://e-crt.org/upload/pdf/crt-2022-882.pdf